The MPP is a public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries, especially for HIV, hepatitis C and tuberculosis treatment. To date, we have secured licences for thirteen antiretrovirals, three hepatitis C direct-acting antivirals, one tuberculosis medicine and an HIV technology platform.

We have sublicensed to many product developers and generic manufacturers to develop and supply medicines in developing countries. Access our “Products licensed” page.

MPP in Numbers

9 patent holders with MPP signed agreements
17 million patient-years through MPP’s generic partners from January 2012 to December 2017
24 generic manufacturers and product developers sublicensed from the MPP
18 products licensed to the MPP
130+ ongoing pharmaceutical development projects
87% to 91%
87% to 91% of people living with HIV in developing countries covered by the MPP adult licences
92 to 131
92 to 131 countries covered by MPP adults licences
553 million dollars saved, from January 2012 to December 2017
  • KPMG calculated savings of USD553 million and supply of 17 million patient-years of treatments through the MPP’s generic partners from January 2012 to December 2017. Read the report.


This website uses cookies to ensure you get the best experience on our website. Learn More